169 related articles for article (PubMed ID: 16984751)
1. Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
Yageman LA; Cronin SM; Peres E; Abidi MH; Ibrahim RB
J Oncol Pharm Pract; 2006 Jun; 12(2):119-21. PubMed ID: 16984751
[TBL] [Abstract][Full Text] [Related]
2. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
McDonnell AM; Lenz KL
Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
[TBL] [Abstract][Full Text] [Related]
3. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
4. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
[TBL] [Abstract][Full Text] [Related]
5. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
Radtke ML; Kolesar JM
J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
[TBL] [Abstract][Full Text] [Related]
6. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.
Fliedner M; Baguet B; Blankart J; Davies M; Henriques E; Leather A; Mazur E; Mihály K; Peeters L; Radványiné A; Sedlackova B
Eur J Oncol Nurs; 2007; 11 Suppl 1():S19-26. PubMed ID: 17540295
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
[TBL] [Abstract][Full Text] [Related]
8. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
9. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
11. Transient oral cavity and skin complications after mucositis preventing therapy (palifermin) in a patient after allogeneic PBSCT. Case history.
Grzegorczyk-Jaźwińska A; Kozak I; Karakulska-Prystupiuk E; Rokicka M; Ganowicz E; Dwilewicz-Trojaczek J; Górska R
Adv Med Sci; 2006; 51 Suppl 1():66-8. PubMed ID: 17460832
[TBL] [Abstract][Full Text] [Related]
12. Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis.
Hueber AJ; Leipe J; Roesler W; Kalden JR; Kallert S; Rech J
Haematologica; 2006 Aug; 91(8 Suppl):ECR32. PubMed ID: 16923516
[TBL] [Abstract][Full Text] [Related]
13. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
14. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.
Abidi MH; Agarwal R; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Zonder J; Ratanatharathorn V; Uberti J
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1455-61. PubMed ID: 22453252
[TBL] [Abstract][Full Text] [Related]
15. Keratinocyte growth factor.
Athar U; Gentile TC
Expert Opin Biol Ther; 2009 Jun; 9(6):779-87. PubMed ID: 19456212
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Beaven AW; Shea TC
Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
[TBL] [Abstract][Full Text] [Related]
17. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
[TBL] [Abstract][Full Text] [Related]
18. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.
Kobbe G; Bruns I; Schroeder T; Czibere A; Warnecke J; Hieronimus N; Safaian N; Kondakci M; Saure C; Germing U; Haas R; Fenk R
Ann Oncol; 2010 Sep; 21(9):1898-1904. PubMed ID: 20233744
[TBL] [Abstract][Full Text] [Related]
19. Natural history of osteonecrosis of the jaw in patients with multiple myeloma.
Badros A; Terpos E; Katodritou E; Goloubeva O; Kastritis E; Verrou E; Zervas K; Baer MR; Meiller T; Dimopoulos MA
J Clin Oncol; 2008 Dec; 26(36):5904-9. PubMed ID: 19018084
[TBL] [Abstract][Full Text] [Related]
20. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.
Montazeri AH; Erskine JG; McQuaker IG
Eur J Haematol; 2007 Jul; 79(1):69-71. PubMed ID: 17598839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
